Earnings ·
ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update
PRQRProQR Therapeutics N.V.
ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update. The company announced positive Phase 1 target engagement data for AX-0810, establishing the first clinical validation of its Axiomer RNA editing platform through NTCP modulation. In June, ProQR closed an underwritten registered direct offering and concurrent private placement with Eli Lilly and Company, raising approximately $59.2 million in gross proceeds. This financing strengthened the balance sheet, bringing cash and cash equivalents to €117.1 million as of June 30, 2026, supporting operations through mid-2028. Net loss for the quarter was €8.7 million, or €0.08 per diluted share, compared to a net loss of €12.2 million in the prior year period. The company anticipates initial Phase 1 data for its next-generation candidate AX-0811 by year-end 2026 and plans to initiate an investigator-initiated trial for biliary atresia in China with data expected in the first half of 2027. ProQR Therapeutics is a clinical-stage biotechnology company developing transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform.